Obsessive Compulsive Disorder (OCD) Drugs Market Report:

Dublin, Oct. 3, 2024 (GLOBE NEWSWIRE) — The “Obsessive Compulsive Disorder Drug Market by Subtype, Drug, Route of Administration, Population Type, End User and Region” report has been added ResearchAndMarkets.com Offer.

The global OCD medication market was $1.06 billion in 2023 and is expected to reach $3.09 billion by 2034, with a compound annual growth rate of 10.23% during the forecast period 2024-2034. The market will grow due to increasing prevalence of OCD, increasing awareness and diagnosis rates, expanding treatment options, government support and initiatives, and personalized medical techniques.

Treatment options for OCD patients have expanded with the advent of novel medications and therapies such as CBT, selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). The development of more precise and effective treatments is driven by ongoing research and innovation in neuroscience and pharmacology, driving market expansion. For example, in January 2023, Eli Lilly reported encouraging results from a Phase 3 clinical trial evaluating its experimental drugs to treat obsessive-compulsive disorder.

Due to higher prevalence of OCD, well-developed healthcare infrastructure, greater awareness of mental disorders and increasing adoption of pharmacological interventions in the North American region, North America is expected to account for the highest revenue share during the forecast period. Furthermore, Asia Pacific is expected to witness the fastest CAGR growth during the forecast period due to increasing recognition of mental health issues, increasing disposable income, increasing healthcare expenditure and improving access to treatment in Asia Pacific. AbbVie, for example, said that starting in November 2023, a Phase 3 program will evaluate a possible treatment for obsessive-compulsive disorder.

This extensive research report focuses on the size and forecasts of global and regional markets from 2023 to 2034.

Report scope:

• Base year: 2023
• Forecast period: 2024-2034
• Study coverage
• Market forecast by subtype, drugs, route of administration, population type and end user
• Market forecast for 5 regions and over 17 countries
  • North America (USA and Canada)
  • Europe (Germany, France, Great Britain, Spain, Italy, Russia, rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
  • Latin America (Brazil, Mexico, Argentina, rest of LATAM)
• MEA (South Africa, GCC, rest of MEA)
• Comprehensive company profiles of the over 10 most important market participants
  • Eli Lilly and Company
  • Pfizer Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Bristol Myers Squibb
  • AstraZeneca PLC
  • Lundbeck A/S
  • Allergan plc
  • Otsuka Pharmaceutical Co. Ltd.
  • H. Lundbeck A/S
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Boehringer Ingelheim International GmbH
  • Mylan NV

Market Analysis and Forecast for Obsessive Compulsive Disorder Drugs, by:

Subtype 2023-2034 (Revenue in billion USD):

• Obsession with contamination with compulsion to wash/clean
• Damage obsessions with controlling compulsions
• Obsessions without visible compulsions
• Symmetry obsessions in ordering
• Organize and count constraints
• Hoard
• Other

By subtype, the “Contamination Obsession with Washing/Cleaning Compulsions” segment was the top-grossing segment in the global OCD medication market in 2023, attributed to increased awareness of hygiene practices due to the COVID-19 pandemic increased demand for treatments that targeting contamination-related OCD symptoms. For example, in August 2023, Talkiatry and NOCD announced a strategic partnership aimed at improving accessibility and outcomes for OCD patients. This collaboration allows them to easily connect with psychiatrists and therapists who specialize in treating the condition. Additionally, the “obsessions without visible compulsions” segment is predicted to grow the fastest during the forecast period as the complexity of OCD is increasingly recognized, leading to improved diagnostic methods and targeted therapeutic approaches tailored to the underlying obsessions without visible compulsions .

Pharmaceuticals 2023-2034 (sales in billion USD):

• Antidepressants
• Antipsychotics
• NMDA blockers
• Other

After medications, the antidepressants segment was the largest revenue segment in the global OCD medication market in 2023, owing to the proven effectiveness of antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), as first-line pharmacological treatments for OCD, supported by extensive clinical evidence Evidence and guidelines recommending their use as a primary therapeutic option. For example, in March 2023, Novartis announced that it would work with a biotech company to develop innovative treatments for mental illnesses such as obsessive-compulsive disorder. Furthermore, the NMDA blockers segment is expected to grow at the fastest CAGR during the forecast period owing to the growing interest in novel treatment mechanisms for glutamatergic dysfunction. NMDA blockers are showing promise in treating treatment-resistant OCD and offer patients new therapeutic options.

Administrative route 2023–2034 (sales in billion USD):

In terms of route of administration, the oral segment was the highest revenue segment in the global OCD medication market in 2023 as oral formulations are convenient, easy to administer and preferred by patients, resulting in widespread acceptance and revenue generation of the OCD -Medicine market. For example, in October 2022, AstraZeneca published encouraging phase 3 trial data for a possible therapy for obsessive-compulsive disorder. Furthermore, the parenteral segment is expected to witness the fastest CAGR growth during the forecast period due to increasing demand for rapid onset of action, improved bioavailability and development of innovative parenteral formulations tailored to specific patient needs and preferences.

Population type 2023-2034 (sales in billion USD):

By population type, the adult segment was the largest revenue segment in the global OCD medication market in 2023 due to higher prevalence of OCD in adults compared to other age groups and increasing demand for pharmaceutical interventions tailored to the specific needs of adult patients. For example, in February 2023, Lundbeck reported that a new application for an OCD therapy had been submitted to the FDA. Additionally, the pediatrics segment is projected to witness the fastest CAGR growth during the forecast period. This is due to increasing recognition of OCD in children and adolescents and efforts to improve early detection and access to treatment, which will drive demand for pediatric OCD drugs and therapies.

End Users 2023-2034 (Revenue in billion USD):

• Hospitals
• Special clinics
• Home health care
• Other

By end-user, the hospitals and specialty clinics segment was the largest segment by revenue in the global obsessive-compulsive disorder drug market in 2023, due to the increasing availability of specialized psychiatric services and facilities in hospitals and specialty clinics that facilitate the diagnosis, treatment and management of obsessive-compulsive disorder, which leads to higher sales in this segment. For example, in October 2022, AstraZeneca published encouraging phase 3 trial data for a possible therapy for obsessive-compulsive disorder. Additionally, the home healthcare segment is projected to witness the fastest CAGR growth during the forecast period, driven by increasing preference for home treatment options, advances in telemedicine, and efforts to improve access to mental health services outside of traditional healthcare, which is driving growth in the home healthcare segment for OCD medication administration and management.

Key attributes

For more information about this report, see

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source of international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

• Global Obsessive Compulsive Disorder Drug Market